SOD1 and amyotrophic lateral sclerosis: This approach is under investigation to treat ALS secondary to mutations in the superoxide dismutase 1 (SOD1) gene, with initial results confirming a reduction in CSF SOD1 protein following intrathecal ASO (BIIB067/tofersen) administration in patients [52].